• Home /
  • Recombinant Antibodies for Immunotherapy Cancer Research.

Recombinant Antibodies for Immunotherapy Cancer Research. Absolute Antibody.

This topic is getting a lot of attention, in the development of cancer therapies. Immunotherapy works by exploiting immune cells to kill cancer cells.  Read BBC news “Immunotherapy cancer drug hailed as “game changer”.

Antibodies against proteins involved in co-stimulation and other aspects of immune cell regulation are of particular interest to therapeutics developers. Some have already entered the clinic, with more in the development pipeline. However, many aspects of immune cell signalling are still unknown, and researchers require ever more advanced tools to tap into this potential.  Our partners at Absolute Antibody use recombinant technology to provide superior monoclonal antibody reagents. In particular, antibody species and isotype can be modified for greater flexibility in vivo. For example, mouse-anti-mouse or rat-anti-rat antibodies can be readily generated.

Ask us about full range of products and services. Can’t find what you are looking for?  Get in touch – we are always happy to hear from you. 

Search and Buy Recombinant Antibodies at competitive prices. Mouse anti-mouse antibodies against immune checkpoint targets - available in any isotypes.

Recombinant Antibodies in the Development of Cancer Therapies.

Mouse

Target

Clone ID

Original

Format

Example: Therapeutic antibodies against human homologues target

CD27

LG. 3A10

Hamster IgG1

Varlilumab [CDX-1127], IgG1 (Celldex Therapeutics)

Phase 2 clinical development for treatment of colorectal cancer, metastatic melanoma, ovarian cancer, renal cell carcinoma, head and neck squamous cell carcinoma and glioblastoma

CD28

D665, E18

Mouse IgG1

Mouse IgG2b

TGN1412, IgG1/4 superagonist (TeGenero)

Withdrawn from clinic due to side effects

CD47

mIAP301

Rat IgG2a

Hu5F9-G4, IgG4 (Forty Seven, Inc)

Phase 1 clinical trial. Indication: solid malignancy or lymphoma.

CD74

In-1

Rat IgG2b

Milatuzumab [hLL1], IgG1 (Immunomedics, Inc)

Phase ½ clinical trial.

Multiple myeloma, non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.

CD134

OX40

Rat IgG1

GSK3174998, IgG (GSK)

Phase 1 clinical trial.

Advanced solid tumor.

CD200

OX90

Rat IgG2a

Samalizumab [ALXN6000], Ig2/4 (Alexion)

Phase 2 clinical trial.

Advanced solid tumor.

CTLA-4

9H10

Hamster IgG2

Ipilimubab, IgG1 (Bristol-Myers Squibb)

In clinic

GITR

YGITR 860.103.5

YGITR 765

Rat IgG2b

Rat IgG2b

TPX518, aglycosyl IgG1 (Leap Therapeutics)

Phase 1 clinical trial.

Solid tumor malignancies.

GITRL

YGL 386

Rat IgG1

 

 

ICOS

7E.17G9

Rat IgG2b

JTX2011 (Jouce Therapeutics)

Phase 1/2a clinical trial. Solid tumor malignancies.

LAG3

YAML 555.6

Rat IgG2b

BMS986016 (Bristol -Myers Squibb)

Phase 1/2a clinical trial. Advanced Solid Tumors

PD-1

RMP1-14

Rat IgG2a

Nivolumab, IgG4 (Bristol -Myers Squibb)

In clinic. Metastatic melanoma.

PDL-1

alphaPD-L1

YDC 127.1.1

Chicken scFv

Rat IgG2a

Durvalumab, IgG1 with engineered Fc to reduce ADCC, CDD (AstraZeneca)

In clinic. Lung cancer.

TOP